JP2020501517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501517A5 JP2020501517A5 JP2019522657A JP2019522657A JP2020501517A5 JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5 JP 2019522657 A JP2019522657 A JP 2019522657A JP 2019522657 A JP2019522657 A JP 2019522657A JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cdna
- subject
- drug
- droplets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000002299 complementary DNA Substances 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 6
- 238000011394 anticancer treatment Methods 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 4
- 108700020796 Oncogene Proteins 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000043276 Oncogene Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 125000006853 reporter group Chemical group 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- 102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 claims 1
- 101710097446 3'(2'),5'-bisphosphate nucleotidase 1 Proteins 0.000 claims 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims 1
- 102100031936 Anterior gradient protein 2 homolog Human genes 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 102100031414 EF-hand domain-containing protein D1 Human genes 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 102100021088 Homeobox protein Hox-B13 Human genes 0.000 claims 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims 1
- 101000775021 Homo sapiens Anterior gradient protein 2 homolog Proteins 0.000 claims 1
- 101000866909 Homo sapiens EF-hand domain-containing protein D1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001041145 Homo sapiens Homeobox protein Hox-B13 Proteins 0.000 claims 1
- 101000739168 Homo sapiens Mammaglobin-B Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100037267 Mammaglobin-B Human genes 0.000 claims 1
- 239000012807 PCR reagent Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101710122111 Probable proline iminopeptidase Proteins 0.000 claims 1
- 101710170844 Proline iminopeptidase Proteins 0.000 claims 1
- 101710122579 Putative proline iminopeptidase Proteins 0.000 claims 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 229940125641 estrogen receptor degrader Drugs 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022142901A JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413952P | 2016-10-27 | 2016-10-27 | |
| US62/413,952 | 2016-10-27 | ||
| PCT/US2017/058855 WO2018081625A2 (en) | 2016-10-27 | 2017-10-27 | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142901A Division JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501517A JP2020501517A (ja) | 2020-01-23 |
| JP2020501517A5 true JP2020501517A5 (enExample) | 2020-12-03 |
| JP7195252B2 JP7195252B2 (ja) | 2022-12-23 |
Family
ID=62025512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522657A Active JP7195252B2 (ja) | 2016-10-27 | 2017-10-27 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
| JP2022142901A Active JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142901A Active JP7441907B2 (ja) | 2016-10-27 | 2022-09-08 | 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11371101B2 (enExample) |
| EP (2) | EP3985127A1 (enExample) |
| JP (2) | JP7195252B2 (enExample) |
| CN (1) | CN110050075B (enExample) |
| WO (1) | WO2018081625A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7144934B2 (ja) | 2015-03-25 | 2022-09-30 | ザ ジェネラル ホスピタル コーポレイション | 血液試料中の循環腫瘍細胞のデジタル分析 |
| EP3985127A1 (en) * | 2016-10-27 | 2022-04-20 | The General Hospital Corporation | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
| WO2020006098A2 (en) * | 2018-06-26 | 2020-01-02 | Children's National Medical Center | Tumor-associated markers for detection of minimal residual disease using digital droplet pcr |
| EP3880198A4 (en) | 2018-11-14 | 2022-08-10 | The Broad Institute, Inc. | Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics |
| TWI790399B (zh) * | 2019-08-30 | 2023-01-21 | 長庚大學 | 循環腫瘤細胞資訊評估方法及其分析方法 |
| WO2021055517A1 (en) * | 2019-09-16 | 2021-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatments based upon molecular characterization of breast cancer |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| JPWO2022196186A1 (enExample) * | 2021-03-16 | 2022-09-22 | ||
| CN113292643A (zh) * | 2021-05-31 | 2021-08-24 | 南京市第二医院 | 一种肝癌肿瘤标志物及其应用 |
| EP4366873A4 (en) * | 2021-07-08 | 2025-08-06 | Ourotech Inc | SYSTEMS AND METHODS FOR PREDICTING TREATMENT EFFECTIVENESS |
| CN114395622A (zh) * | 2021-12-13 | 2022-04-26 | 深圳先进技术研究院 | 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US889A (en) | 1838-08-20 | Mode of constructing metal bench-vises | ||
| US8535A (en) | 1851-11-18 | Stove-geate | ||
| DE29623597U1 (de) | 1996-11-08 | 1999-01-07 | Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg | Temperierblock mit Temperiereinrichtungen |
| US20080050393A1 (en) | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
| CA2311201A1 (en) | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
| EP1353947A2 (en) | 2000-12-08 | 2003-10-22 | Ipsogen | Gene expression profiling of primary breast carcinomas using arrays of candidate genes |
| US20030064385A1 (en) | 2001-05-16 | 2003-04-03 | Dressman Marlene Michelle | Genes expressed in breast cancer as prognostic and therapeutic targets |
| US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US20070026417A1 (en) | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| WO2006121991A2 (en) * | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
| WO2007136717A1 (en) | 2006-05-16 | 2007-11-29 | Nugen Technologies, Inc. | Nucleic acid separation and purification method based on reversible charge interactions |
| US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
| WO2009051734A1 (en) | 2007-10-17 | 2009-04-23 | The General Hospital Corporation | Microchip-based devices for capturing circulating tumor cells and methods of their use |
| US9068181B2 (en) | 2008-05-23 | 2015-06-30 | The General Hospital Corporation | Microfluidic droplet encapsulation |
| US20120252015A1 (en) | 2011-02-18 | 2012-10-04 | Bio-Rad Laboratories | Methods and compositions for detecting genetic material |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US9625454B2 (en) | 2009-09-04 | 2017-04-18 | The Research Foundation For The State University Of New York | Rapid and continuous analyte processing in droplet microfluidic devices |
| US20110166030A1 (en) | 2009-09-30 | 2011-07-07 | Yixin Wang | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells |
| EP4484577A3 (en) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US20120329061A1 (en) | 2010-03-11 | 2012-12-27 | Board Of Regents, The University Of Texas System | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients |
| MX2012011167A (es) * | 2010-03-31 | 2013-02-07 | Sividon Diagnostics Gmbh | Metodo para prediccion de recurrencia de cancer de mama bajo tratamiento endocrino. |
| AU2015268617A1 (en) * | 2010-03-31 | 2016-01-07 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment |
| US9650629B2 (en) | 2010-07-07 | 2017-05-16 | Roche Molecular Systems, Inc. | Clonal pre-amplification in emulsion |
| WO2012024543A1 (en) | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| WO2012135397A2 (en) * | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| CN104011543B (zh) | 2011-10-24 | 2016-06-15 | 通用医疗公司 | 癌症的生物标记 |
| US9766244B2 (en) * | 2012-07-02 | 2017-09-19 | The General Hospital Corporation | Diagnosis and monitoring treatment of prostate cancer |
| GB2539836B (en) | 2012-08-13 | 2017-03-29 | Univ California | Methods for detecting target nucleic acids in sample lysate droplets |
| EP2895625B1 (en) * | 2012-09-14 | 2018-04-18 | Memorial Sloan-Kettering Cancer Center | Genes associated with dasatinib sensitivity |
| US9671405B2 (en) * | 2012-09-19 | 2017-06-06 | Cornell University | Identifying taxane sensitivity in prostate cancer patients |
| WO2014075067A1 (en) * | 2012-11-12 | 2014-05-15 | Nanostring Technologies, Inc. | Methods to predict breast cancer outcome |
| US20140303005A1 (en) | 2013-04-05 | 2014-10-09 | Raindance Technologies, Inc. | Rare cell analysis after negative selection |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| EP3058316B1 (en) | 2013-10-18 | 2019-03-13 | The General Hospital Corporation | Microfluidic sorting using high gradient magnetic fields |
| WO2015136017A1 (en) * | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| JP2017515873A (ja) * | 2014-05-21 | 2017-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法 |
| JP6782698B2 (ja) * | 2014-12-12 | 2020-11-11 | セルキュイティー インコーポレイテッド | がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法 |
| CN107250385B (zh) | 2015-02-20 | 2021-03-09 | 考麦兹股份公司 | 用于切割天然皮革及类似物的方法 |
| MA45480A (fr) * | 2015-03-12 | 2018-01-17 | Janssen Pharmaceutica Nv | Marqueurs d'arnm à base de sang total pour prédire un cancer de la prostate, et leurs procédés de détection |
| JP7144934B2 (ja) | 2015-03-25 | 2022-09-30 | ザ ジェネラル ホスピタル コーポレイション | 血液試料中の循環腫瘍細胞のデジタル分析 |
| EP3985127A1 (en) * | 2016-10-27 | 2022-04-20 | The General Hospital Corporation | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
-
2017
- 2017-10-27 EP EP21212237.8A patent/EP3985127A1/en active Pending
- 2017-10-27 CN CN201780075515.XA patent/CN110050075B/zh active Active
- 2017-10-27 US US16/344,557 patent/US11371101B2/en active Active
- 2017-10-27 JP JP2019522657A patent/JP7195252B2/ja active Active
- 2017-10-27 EP EP17865612.0A patent/EP3532642B1/en active Active
- 2017-10-27 WO PCT/US2017/058855 patent/WO2018081625A2/en not_active Ceased
-
2022
- 2022-05-27 US US17/826,834 patent/US12331363B2/en active Active
- 2022-09-08 JP JP2022142901A patent/JP7441907B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501517A5 (enExample) | ||
| Alba-Bernal et al. | Challenges and achievements of liquid biopsy technologies employed in early breast cancer | |
| Blassl et al. | Gene expression profiling of single circulating tumor cells in ovarian cancer–Establishment of a multi-marker gene panel | |
| Vriens et al. | MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer | |
| Mego et al. | Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy | |
| Fabris et al. | The potential of microRNAs as prostate cancer biomarkers | |
| Redis et al. | CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations | |
| Song et al. | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients | |
| Torres et al. | Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients | |
| Zhang et al. | Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma | |
| Liu et al. | miR‐7 modulates chemoresistance of small cell lung cancer by repressing MRP 1/ABCC 1 | |
| MacConaill et al. | Prospective enterprise-level molecular genotyping of a cohort of cancer patients | |
| Schneck et al. | Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients | |
| Wang et al. | Comprehensive analysis of aberrantly expressed profiles of lncRNAs and miRNAs with associated ceRNA network in muscle-invasive bladder cancer | |
| Chan et al. | SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients | |
| Peng et al. | Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma | |
| Daniunaite et al. | Clinical significance of miRNA host gene promoter methylation in prostate cancer | |
| Kulda et al. | Prognostic significance of TMPRSS2-ERG fusion gene in prostate cancer | |
| Marino et al. | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression | |
| Shinmei et al. | MicroRNA‐155 is a predictive marker for survival in patients with clear cell renal cell carcinoma | |
| Kowalczyk et al. | SATB1 is down-regulated in clear cell renal cell carcinoma and correlates with miR-21-5p overexpression and poor prognosis | |
| Suer et al. | MicroRNAs as prognostic markers in prostate cancer | |
| US20110165566A1 (en) | Methods of optimizing treatment of breast cancer | |
| Hou et al. | Identification of microRNA-205 as a potential prognostic indicator for human glioma | |
| JP2018513679A5 (enExample) |